Histopathological Grade versus Estrogen and Progestron Receptor Status in Carcinoma Breast- A Single Center Study

Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012 (second most common cancer overall). This represents about 12% of all new cancer cases and 25% of all cancers in women [1]. Breast cancer is a leading cause of death in women [2]. Incidence of breast cancer is low in India compared to western countries, but it is associated with poor prognosis and high mortality, may be due to late presentation at advanced stages [3]. It shows heterogeneity in its clinical behavior. Prognosis and management of breast cancer are influenced by the classic variables such as histological type and grade, tumor size, lymph node status, status of hormonal receptorsestrogen receptor (ER) and Progesterone receptor (PR) of tumor [4]. Determining the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (Her2/neu) receptor status in breast cancer has become practice as survival advantage for patients with hormones receptor positive status by treatment with adjuvant hormonal or chemotherapeutic regimens . It is well known that strong ER-positive cases benefit from endocrine therapy alone, in contrast to those with low to moderate ER positivity [5].